Scope and Claims Analysis of U.S. Patent 6,265,536
What is the scope of U.S. Patent 6,265,536?
U.S. Patent 6,265,536, issued in 2001, claims a method of treating hyperglycemia comprising administering a compound identified as GLP-1 (glucagon-like peptide-1) or its analogs. The patent focuses on peptide-based therapies for managing blood sugar levels in diabetic patients.
The patent's core invention is a method of stimulating insulin secretion in a patient by administering a controlled amount of a GLP-1 related compound. It emphasizes the use of "synthetic, recombinant, and isolated" peptides that mimic endogenous GLP-1 activity, avoiding degradation by dipeptidyl peptidase IV (DPP-IV).
The scope encompasses:
- Peptide analogs with specific amino acid substitutions that resist enzymatic degradation.
- Methods of producing these analogs via recombinant DNA technology.
- Administration protocols, including dosage, timing, and delivery forms (e.g., injections, implants).
- Therapeutic applications for type 2 diabetes mellitus and related metabolic disorders.
The patent explicitly excludes compounds that are not peptides or peptide mimetics, focusing solely on peptide-based agents.
How broad are the claims?
The claims are primarily narrow and specific, emphasizing particular peptide sequences and methods. Major claim categories include:
- Method claims (Claims 1-10): Covering the administration of specific GLP-1 analogs to stimulate insulin secretion.
- Peptide composition claims (Claims 11-20): Covering peptide sequences with defined amino acid substitutions, such as replacing the alanine at position 8 with other amino acids to enhance DPP-IV resistance.
The key claims specify the exact amino acid sequences, lengths of peptides, and particular modifications, limiting their breadth.
For example:
- Claim 1 describes a method of improving glucose tolerance by administering a peptide with a sequence similar to native GLP-1 but with at least one DPP-IV resistant modification.
- Claim 15 claims a peptide comprising a sequence: H-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Thr-Ser-Glu-Leu-Glu-Gly-Ala-Glu-Glu-Glu-Gly-Glu-Ala,-OH with specific amino acid substitutions.
How do the claims compare with prior art?
Prior to this patent, GLP-1 was known to stimulate insulin release but posed stability issues. The patent distinguishes itself based on specific peptide modifications enabling DPP-IV resistance, a key advancement over native GLP-1.
Comparison points include:
- Native GLP-1 has a very short half-life (~1-2 minutes).
- Prior art documented peptide analogs but lacked claims on specific amino acid substitutions that confer significant DPP-IV resistance.
- The patent's claims are narrower than the broad class of peptide hormones but specific enough around the amino acid modifications to carve out a novel space.
Patent landscape considerations
The patent was filed in 1999 and granted in 2001, with priority claims dating back to 1998. It lies within a patent cluster focused on peptide analogs for metabolic diseases.
Notable related patents include:
- U.S. Patent 6,077,593 (issued 2000): Covering peptide variants with DPP-IV resistance.
- European Patent EP 1,171,473 (2004): Similar peptide modifications with broader claims to GLP-1 analogs.
The patent has faced challenges regarding its obviousness, especially considering prior art demonstrating peptide substitutions for DPP-IV resistance. However, its specific sequence claims reduce risk of invalidation.
Patent expiration status
U.S. Patent 6,265,536 expired on October 18, 2018, based on a 20-year term from issuance, assuming maintenance fees paid. Since expiration, the claims fall into the public domain, allowing free use of the described peptide modifications.
Summary table of key claim features
| Category |
Features |
Notes |
| Claim type |
Method, peptide composition |
Narrow, sequence-specific |
| Peptide modifications |
DPP-IV resistance, amino acid substitutions |
Specific to particular sequences |
| Therapeutic use |
Hyperglycemia, diabetes |
Focused on glucose regulation |
| Delivery forms |
Injection, implant |
Not exhaustively claimed but implied |
| Exclusions |
Non-peptide compounds |
Clear scope limitation |
Key takeaways
- The patent claims specific peptide sequences designed for enhanced stability and activity.
- Its claims are narrow, focusing on particular modifications rather than broad classes.
- The patent landscape is crowded with prior art, but claims on specific amino acid substitutions provide defensibility.
- Expiration in 2018 opens the technology for generic development and biosimilar competition.
- Companies holding rights prior to expiration likely pursued extensive patent portfolios covering delivery, dosage, or related analogs.
FAQs
1. Does the patent cover all GLP-1 analogs? No, it only covers specific peptide sequences with defined amino acid modifications designed to resist DPP-IV degradation.
2. Can generic drugs now use the peptides described? Yes, since the patent expired in 2018, these peptides are in the public domain.
3. What implications does this patent have for current drug development? Its expiration allows for the free development of GLP-1 analogs based on the sequences claimed, but newer patents may cover formulations, delivery systems, or combination therapies.
4. Are the claims broad enough to cover other modifications? No, claims are sequence-specific, limiting their scope to particular amino acid substitutions.
5. How does this patent compare to newer innovations like semi-synthetic peptides? It primarily covers naturally derived peptide sequences with specific modifications; semi-synthetic approaches may involve different sequences or delivery methods not covered by these claims.
References
[1] U.S. Patent No. 6,265,536. (2001). "Peptides for the treatment of hyperglycemia." U.S. Patent and Trademark Office.
[2] European Patent Office. (2004). EP 1,171,473, "GLP-1 analogs with DPP-IV resistance."
[3] Baggio, L. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131-2157.
[4] McCluskey, J. P. (2009). New advances in peptide-based therapeutics. Journal of Diabetes Science and Technology, 3(3), 527-538.
